Hims & Hers Shares Slide 5.7% After GLP-1 Rollout Drives Sharp Gross Margin Decline
Hims & Hers Health (HIMS) shares fell 5.7% to $29.96 premarket after its quarter ended June 30 showed gross margin down to 64% from 76% and a wider loss of $86.3 million. Revenue rose to $753.2 million and subscribers to 2.89 million. The company lowered the adjusted EBITDA midpoint by $12.5 million and reduced the upper end by $25 million.
How this was made
The 30-second read
Why it matters
The key tradable change is the combination of weaker profitability metrics (gross margin down to 64%) and a guidance reset (lowered adjusted EBITDA midpoint by $12.5 million), alongside negative free cash flow.
Market read
Traders can act on a fresh profitability/guidance shock: margin compression is worsening and the EBITDA outlook midpoint is reduced, aligning with the stock’s premarket selloff.
What to watch
The article notes Eucalyptus contribution and restructuring charges; investors may be over-weighting one-time portfolio transition costs versus normalized margins.
Background
Hims is scaling branded GLP-1 weight-loss offerings and expanding overseas, but the company’s growth strategy is associated with lower gross margins.
Ticker impact
Hims shares fell 5.7% premarket after Q2 gross margin dropped to 64% from 76% and guidance cut the EBITDA midpoint.
Bearish bias for the next few sessions as investors reprice sustained sub-avg gross margins and weaker EBITDA conversion.
The article cites a fourth consecutive gross margin decline, a wider quarterly loss, negative free cash flow, and a lowered adjusted EBITDA outlook midpoint.
Market effects
Signals that GLP-1 commercialization and branded-drug mix can structurally pressure gross margins for telehealth/consumer health platforms.
Limited, primarily US-listed growth/consumer health sentiment.
Moderate, as overseas expansion is cited as a growth driver but with slimmer margins.
Counterpoint
Revenue growth and subscriber gains (2.89M, +38% revenue) could eventually offset margin pressure if purchasing terms and operating leverage improve.
Key entities
- public_companyHims & Hers Health
Telehealth company reporting Q2 results with gross margin decline and revised full-year adjusted EBITDA guidance.
- executiveAndrew Dudum
CEO quoted on providing care at a global scale and reasonable price.
- executiveYemi Okupe
CFO quoted that core business beat prior sales outlook excluding Eucalyptus.
